Antengene Corporation Limited (722) Price & Analysis

0 Followers

722 Stock Chart & Stats

€0.53

>-€0.01(-1.45%)

At close: Jan 08 4:00 PM EST

€0.53

>-€0.01(-1.45%)

Day’s Range― - ―

52-Week Range€0.29 - €0.65

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€223.90M

Enterprise Value€1.68B

Total Cash (Recent Filing)€764.90M

Total Debt (Recent Filing)€257.88M

Price to Earnings (P/E)32.0

Beta1.02

Next Earnings

Mar 19, 2027

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.08

Shares Outstanding689,536,600

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)3.32

Price to Sales (P/S)20.24

P/FCF Ratio-11.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€1.13

Price Target Upside114.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.05

Revenue Forecast (FY)€95.86M

Bulls Say, Bears Say

Bulls Say

Revenue Growth AccelerationThe return to meaningful revenue growth indicates improving commercial traction after a stagnant prior year. If sustained, stronger top-line expansion can increase operating leverage, support broader investment in the pipeline, and improve the company’s ability to absorb substantial research and development costs.

Losses And Cash Burn NarrowingAlthough the company remains unprofitable, the reduction in losses and cash consumption represents progress in financial discipline and operating momentum. Continued improvement could extend the funding runway, reduce dependence on external capital, and provide a stronger foundation for scaling approved products and advancing clinical programs.

Improving Balance-sheet LeverageLow and declining debt relative to equity gives Antengene greater balance-sheet flexibility while it funds clinical development and commercialization. Modest leverage limits fixed financing obligations and leaves more capacity to manage uncertainty, pursue growth opportunities, or withstand periods of continued operating losses.

Bears Say

Persistent Deep LossesThe company has not yet reached a sustainable earnings model, meaning revenue and gross profit remain insufficient to cover operating and development expenses. Persistent net losses can erode capital, constrain reinvestment, and make future financial performance highly dependent on clinical and commercial execution.

Negative Free Cash FlowAntengene continues to consume substantial cash rather than funding operations internally. Even with improved cash-flow trends, ongoing negative free cash flow can require reliance on existing capital or future financing, limiting strategic flexibility and increasing the importance of successful approvals and product revenue growth.

Gross-margin CompressionThe material decline in gross margin weakens the quality of revenue growth and reduces the amount available to offset research, development, and commercial expenses. If the lower margin persists, Antengene may need substantially greater revenue scale before its improving top line can translate into sustainable profitability.

Antengene Corporation Limited News

Antengene Grants 11.52 Million RSUs Under 2022 Incentive Scheme

Antengene Corporation Limited ( ($HK:6996) ) has issued an announcement. Antengene Corporation Limited has granted 11,520,000 restricted share...

1M ago

Antengene Wins Australian Approval to Begin Phase I Trial of Autoimmune Drug ATG-201

Antengene Corporation Limited ( ($HK:6996) ) just unveiled an announcement. Antengene Corporation Limited has secured Human Research Ethics...

2M ago

Antengene Swings to Interim Profit on Licensing-Driven Revenue Surge

The latest update is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited reported a sharp...

2M ago

Antengene Sets Board Meeting to Approve 2026 Interim Results

Antengene Corporation Limited ( ($HK:6996) ) just unveiled an update. Antengene Corporation Limited has scheduled a board meeting...

2M ago

Antengene Updates Board Composition and Committee Roles

Antengene Corporation Limited ( ($HK:6996) ) has issued an announcement. Antengene Corporation Limited announced the current composition of...

3M ago

Antengene Reshapes Leadership Team With CFO Exit and New Executive Appointments

The latest update is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited announced the resignation...

3M ago

Antengene Signals Major Interim Profit on Oncology Licensing Deals

Antengene Corporation Limited ( ($HK:6996) ) has issued an announcement. Antengene has issued a positive profit alert for...

3M ago

Antengene Secures USD60 Million Upfront from UCB for ATG-201 License

Antengene Corporation Limited ( ($HK:6996) ) has issued an announcement. Antengene Corporation Limited announced it has received a...

3M ago

Antengene Launches HK$50 Million Share Buyback Plan

The latest announcement is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited has announced a...

4M ago

Antengene Out-Licenses ATG-106 to K2 Therapeutics in Potential US$1.9 Billion TCE Deal

Antengene Corporation Limited ( ($HK:6996) ) has issued an update. Antengene has entered into an exclusive, sublicensable license...

4M ago

722 FAQ

What was Antengene Corporation Limited’s price range in the past 12 months?

Antengene Corporation Limited lowest stock price was €0.29 and its highest was €0.65 in the past 12 months.

What is Antengene Corporation Limited’s market cap?

Antengene Corporation Limited’s market cap is €223.90M.

When is Antengene Corporation Limited’s upcoming earnings report date?

Antengene Corporation Limited’s upcoming earnings report date is Mar 19, 2027 which is in 147 days.

How were Antengene Corporation Limited’s earnings last quarter?

Antengene Corporation Limited released its earnings results on Aug 21, 2026. The company reported €0.045 earnings per share for the quarter, missing the consensus estimate of €0.048 by -€0.004.

Is Antengene Corporation Limited overvalued?

According to Wall Street analysts Antengene Corporation Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Antengene Corporation Limited pay dividends?

Antengene Corporation Limited does not currently pay dividends.

What is Antengene Corporation Limited’s EPS estimate?

Antengene Corporation Limited’s EPS estimate is 0.02.

How many shares outstanding does Antengene Corporation Limited have?

Antengene Corporation Limited has 689,536,600 shares outstanding.

What happened to Antengene Corporation Limited’s price movement after its last earnings report?

Antengene Corporation Limited reported an EPS of €0.045 in its last earnings report, missing expectations of €0.048. Following the earnings report the stock price went down -3.333%.

Which hedge fund is a major shareholder of Antengene Corporation Limited?

Currently, no hedge funds are holding shares in DE:722

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Antengene Corporation Limited

Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.

Antengene Corporation Limited (722) Earnings & Revenues

Historic Earnings Reports

722 Stock 12 Month Forecast

Average Price Target

€1.13

▲(114.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.13423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.13423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.13423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.37,0.42878692307692307,0.48757384615384614,0.5463607692307693,0.6051476923076924,0.6639346153846154,0.7227215384615385,0.7815084615384615,0.8402953846153847,0.8990823076923078,0.9578692307692308,1.0166561538461538,1.0754430769230772,{"y":1.13423,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.37,0.42878692307692307,0.48757384615384614,0.5463607692307693,0.6051476923076924,0.6639346153846154,0.7227215384615385,0.7815084615384615,0.8402953846153847,0.8990823076923078,0.9578692307692308,1.0166561538461538,1.0754430769230772,{"y":1.13423,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.37,0.42878692307692307,0.48757384615384614,0.5463607692307693,0.6051476923076924,0.6639346153846154,0.7227215384615385,0.7815084615384615,0.8402953846153847,0.8990823076923078,0.9578692307692308,1.0166561538461538,1.0754430769230772,{"y":1.13423,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.468,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.396,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.306,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.406,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.374,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.414,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.372,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >